Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ONC-392 |
| Trade Name | |
| Synonyms | ONC392|ONC 392|Gotistobart|BNT316|BNT 316|BNT-316 |
| Drug Descriptions |
ONC-392 is a pH-sensitive monoclonal antibody that targets CTLA4 (CD152), potentially resulting in antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
| DrugClasses | CTLA4 Antibody 33 Immune Checkpoint Inhibitor 150 |
| CAS Registry Number | 2226344-78-9 |
| NCIT ID | C173547 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BNT116 + ONC-392 | BNT116 ONC-392 | 0 | 1 |
| lutetium Lu 177 vipivotide tetraxetan + ONC-392 | ONC-392 lutetium Lu 177 vipivotide tetraxetan | 0 | 1 |
| ONC-392 | ONC-392 | 0 | 2 |
| ONC-392 + Pembrolizumab | ONC-392 Pembrolizumab | 0 | 2 |